期刊文献+

左氧氟沙星的血药浓度指导肺结核患者剂量选择的临床观察 被引量:9

下载PDF
导出
摘要 目的通过血药浓度监测为肺结核患者应用左氧氟沙星治疗剂量的选择提供参考依据,并明确血药浓度监测在结核病治疗中的意义。方法选取涂阳耐药肺结核患者120例,随机分为4组,每组30例,在接受抗结核药物治疗的同时,分别每日接受不同剂量左氧氟沙星400mg、600mg、800mg、1000mg,治疗7天,在服药后2、6小时分别取血浆样本测定血药浓度,监测药物不良反应。结果 400mg/d左氧氟沙星血药峰浓度(Cmax)的中位数是7.463μg/ml,仅有33%的患者达到治疗浓度范围;600mg/d左氧氟沙星Cmax的中位数是9.463μg/ml,有65%患者达到治疗浓度范围;800mg/d左氧氟沙星Cmax的中位数是12.463μg/ml,达到治疗浓度范围为97%;1000mg/d左氧氟沙星Cmax的中位数是14.6μg/ml,达到治疗浓度范围为100%。4组间两两比较,差异均有显著性(P<0.05),不良反应发生率无明显差异。结论目前常规应用左氧氟沙星400mg/d剂量难以达到有效的治疗效果,加强抗结核药血药浓度监测对结核病患者合理用药具有重要意义。
出处 《中国临床医生杂志》 2013年第3期49-50,共2页 Chinese Journal For Clinicians
基金 "十二五"重大新药创制科技重大专项课题 "抗结核药物新药临床评价研究技术平台建设"(2012ZX09303002)
  • 相关文献

参考文献11

  • 1Rodriguez JC, Ruiz M, Lopez M,et al. In vitro activity of moxifloxa- cin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis[ J. Int J Antimicrob Agents,2002,20 (6) :464-467.
  • 2Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo ac- tivities of gatifloxacin against Mycobaeterium tuberculosis [ J ] - Anti- mierob Agents Chemother,2002,46(4) :1022-1025.
  • 3Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-contai- ning regimen greatly reduces time to culture conversion in murine tu- berculosis[ J]. Am J Respir Crit Care Med, 2004, 169 ( 3 ) :421 - 426.
  • 4Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-contai- ning regimens of reduced duration produce a stable cure in murine tu- berculosis [ J ]. Am J Respir Crit Care Med, 2004, 170 (10) : 1131-1134.
  • 5Chien SC,Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers [ J ]. Antimi- crob Agents Chemother, 1998,42(4) :885-888.
  • 6Goldstein E J, Garabedian-Ruffalo SM. Widespread use of fluoroquin- olones versus emerging resistance in pneumococci [ J ]. Clin Infect Dis,2002,35(12) :1505-1511.
  • 7Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories[ Jl. Clin Infect Dis, 2001,32 Suppl 1 :$39-46.
  • 8Peloquin C/( Hadad D J, Molino LP, et al. Population pharmacoki- netics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis [ J ]. Antimicrob Agents Chemother, 2008,52 (3) :852-857.
  • 9Braum JT, Daley CL, Desmond EP, et al. Drug-Resistant Tubercu- losis:A Survival Guide for Clinicians[ J ]. Curry National Tuberculo- sis Center and California Department of Public Health, 2008,2:49 - 66.
  • 10Falzon D, Jaramillo E, Sehunemann H J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update[J]. Eur Respir J,2011,38(3) :516-528.

同被引文献85

引证文献9

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部